National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
With the aim to explore the anti-tumour effect of Withaferin A in DMBA (7,12-dimethylbenz[a]anthracene) induced mammary tumour in rats, seventy two female Sprague-Dawley rats were equally distributed to control, DMBA, tamoxifen and Withaferin A groups. Tamoxifen, which is widely used as first-line drug in the treatment of estrogen positive breast cancer was taken as standard for comparison. The study was conducted for a period of 16 weeks. DMBA (5 mg/rat/week/per os) at 4 weekly doses were used for tumour induction. Piloerection was noticed after DMBA administration. Tumour latency, location, incidence, frequency, size, volume and weight were recorded. Hundred per cent tumour formation in DMBA alone administered animal was observed. No metastasis was recorded. Abdominal glands were most frequently affected in all DMBA administered groups. Withaferin A group showed 17% tumour inhibition and the number of tumours were almost equal to that of DMBA group. Higher incidence of carcinomas (65%) and lower incidence of benign (35%) mammary tumours were observed in Withaferin A group with maximum tumour frequency of seven tumours/rat when compared with tamoxifen group. Hence further investigations are required.
Citations |
 |
 |
 |
 |
